Roesch and colleagues found that melanoma cell lines treated with diverse anticancer drugs, such as cisplatin, bortezomib, and the BRAF inhibitor vemurafenib, were enriched for resistant JARID1Bhigh melanoma cells with increased expression of mitochondrial proteins involved in bioenergetic metabolism [60]. The gene discussed is BRAF; the disease is melanoma.